Hong Yang

Hong Yang

Auto-generated profile, based on publicly available information

Hong Yang

Office of Biostatistics and Pharmacovigilance, Center for Biologics Evaluation and Research, US FDA, Silver Spring, USA

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 April 2021 in The AAPS Journal
Verified
Journal Article
Closed access
PDF file
UNUjwani Nukala
Ujwani Nukala
MMMarisabel Rodriguez Messan
Marisabel Rodriguez Messan
OYOsman N. Yogurtcu
Osman N. Yogurtcu
XWXiaofei Wang
Xiaofei Wang
HYHong Yang
Hong Yang

10 September 2020 in Blood
Verified
Journal Article
Open access
PDF file
EGEduard Grebe
Eduard Grebe
MBMichael P. Busch
Michael P. Busch
ENEdward P. Notari
Edward P. Notari
RBRoberta Bruhn
Roberta Bruhn
CQClaire Quiner
Claire Quiner
BCBrian Custer
Brian Custer
In 2015, the US Food and Drug Administration published revised guidance that recommended a change in blood donor deferral of men who have sex with men (MSM) from an indefinite to a 12-month deferral since the donor last had sex with a man. We assessed whether HIV incidence in first-time blood donors or associated transfusion risk increased. Donations in 4 major blood collection organizations were monitored for 15 months before and 2 years after implementation of the 12-month MSM deferral policy. HIV-positive donations were classified as recently acquired or long-term using a recent infection testing algorithm and incidence in both periods estimated. Residual transfusion transmission risk was estimated by multiplying incidence by the length of the infectious window period. The latter was estimated using a model based on infectious dose and the sensitivity of nucleic acid testing. Factors associated with incident infection in each period were assessed using Poisson regression. Overall HIV incidence in first-time donors before implementation of the 12-month MSM deferral was estimated at 2.62 cases per 100 000 person-years (105 PY) (95% credible interval [CI], 1.53-3.93 cases/105 PY), and after implementation at 2.85 cases/105 PY (95% CI, 1.96-3.93 cases/105 PY), with no statistically significant change. In male first-time donors, the incidence difference was 0.93 cases/105 PY (95% CI, −1.74-3.58 cases/105 PY). The residual risk of HIV transfusion transmission through components sourced from first-time donors was estimated at 0.32 transmissions per million (106) packed red blood cell transfusions (95% CI, 0.29-0.65 transmissions/106 transfusions) before and 0.35 transmissions/106 transfusions (95% CI, 0.31-0.65 transmissions/106 transfusions) after implementation. The difference was not statistically significant. Factors associated with incident infection were the same in each period. We observed no increase in HIV incidence or HIV transfusion transmission risk after implementation of a 12-month MSM deferral policy.

28 March 2022 in Vaccine
Verified
Journal Article
Closed access
PFPatrick R. Funk
Patrick R. Funk
OYOsman N. Yogurtcu
Osman N. Yogurtcu
RFRichard A. Forshee
Richard A. Forshee
SASteve A. Anderson
Steve A. Anderson
PMPeter W. Marks
Peter W. Marks
HYHong Yang
Hong Yang

3 June 2011 in Transfusion
Verified
Journal Article
Closed access
PDF file
LGLuisa Gregori
Luisa Gregori
HYHong Yang
Hong Yang
SASteven Anderson
Steven Anderson

2 August 2019 in The AAPS Journal
Verified
Journal Article
Closed access
OYOsman N. Yogurtcu
Osman N. Yogurtcu
ZSZuben E. Sauna
Zuben E. Sauna
JMJoseph R. McGill
Joseph R. McGill
MTMillion A. Tegenge
Million A. Tegenge
HYHong Yang
Hong Yang

1 April 2014 in Transfusion
Verified
Journal Article
Closed access
PDF file
HYHong Yang
Hong Yang
LGLuisa Gregori
Luisa Gregori
DADavid M. Asher
David M. Asher
JEJay S. Epstein
Jay S. Epstein
SASteven A. Anderson
Steven A. Anderson